HaTay Pharmaceutical JSC

HaTay Pharmaceutical JSC ROE

The Return on Equity (ROE) of HaTay Pharmaceutical JSC (DHT.VN) as of Nov 2, 2026 is 6.97 %. In the previous year, Return on Equity (ROE) was 8.19 % — a change of -14.90% (lower).

ROE

6.97 %

YoY

-14.90%

Last updated:

In 2024, HaTay Pharmaceutical JSC's return on equity (ROE) was 6.97 %, a -14.90% increase from the 8.19 % ROE in the previous year.

The HaTay Pharmaceutical JSC ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2017
31.64 VND
Jan 1, 2018
32.45 VND
Jan 1, 2019
29.87 VND
Jan 1, 2020
28.22 VND
Jan 1, 2021
9.31 VND
Jan 1, 2022
12.31 VND
Jan 1, 2023
8.19 VND
Jan 1, 2024
6.97 VND
The HaTay Pharmaceutical JSC ROE history
YEARROEYoY
6.97 %-14.90%
8.19 %-33.46%
12.31 %+32.23%
9.31 %-67.00%
28.22 %-5.53%
29.87 %-7.97%
32.45 %+2.56%
31.64 %+11.49%
28.38 %+18.76%
23.90 %+19.31%
20.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

HaTay Pharmaceutical JSC Stock analysis

What does HaTay Pharmaceutical JSC do? Ha Tay Pharmaceutical JSC generates revenue through the manufacturing, import, and export of pharmaceuticals, cosmetics, and medical equipment. The company sells its products via wholesale and retail channels, targeting healthcare providers, pharmacies, and consumers. It also engages in the production and trading of cosmetic products, supplemental food, and laboratory chemicals, alongside medical equipment and supplies. The firm completed the acquisition of a 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company in 2013, expanding its market presence in pharmaceuticals and medical equipment. The company operates in the pharmaceutical sector, serving healthcare institutions, retail pharmacies, and end consumers. Its revenue streams include the sale of drugs, cosmetics, medical equipment, and related supplies. Additional income comes from supermarket operations, real estate leasing, and vocational training services, though these are secondary to its core pharmaceutical business. Ha Tay Pharmaceutical JSC's primary customers are healthcare providers, pharmacies, and consumers purchasing pharmaceuticals, cosmetics, and medical equipment. The firm's product portfolio spans drugs, vaccines, cosmetic products, supplemental food, and laboratory chemicals, with a focus on manufacturing and trading. The acquisition of the 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company has strengthened its position in the medical equipment market. HaTay Pharmaceutical JSC is one of the most popular companies on Eulerpool.

ROE Details

Decoding HaTay Pharmaceutical JSC's Return on Equity (ROE)

HaTay Pharmaceutical JSC's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing HaTay Pharmaceutical JSC's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

HaTay Pharmaceutical JSC's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in HaTay Pharmaceutical JSC’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about HaTay Pharmaceutical JSC stock

Return on Equity (ROE) of HaTay Pharmaceutical JSC is 6.97 % in 2024.

Return on Equity (ROE) of HaTay Pharmaceutical JSC changed from 8.19 % to 6.97 %, representing a -14.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) HaTay Pharmaceutical JSC since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s HaTay Pharmaceutical JSC with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — HaTay Pharmaceutical JSC

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — HaTay Pharmaceutical JSC